Kenvue Marks Independence By Extending Motrin And Tylenol Lines With Help From A Competitor
Kenvue also not standing apart from competitors concerning headwinds from foreign exchange rates, a slow start to the cough/cold season and looking ahead to FDA decision on oral phenylephrine, it reports with its third-quarter results.
You may also be interested in...
Attacks on shipping since November in the Red Sea lead shipping lines to re-route vessels south of Africa, spiking shipping costs. Perrigo began 2024 saying it expects sales of Opill oral contraceptive to start early in the first quarter, but now expects to start late in the quarter.
CEO Thibaut Mongon says Kenvue’s priorities since separation from J&J include “maybe something that was not obvious in the previous world,” when employees “could not relate to how” their work mattered. North America president change comes with skin health and beauty portfolio “not where we want to be.”
During Kenvue’s first earnings briefing, CEO Thibaut Mongon touts adding products and extending lines but repeatedly references attention to fundamentals of manufacturing and marketing OTC drugs, personal and skin care lines and other consumer health products.